Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review

Clinical and Experimental Ophthalmology

Volumn 44, Issue 4, 2016, Pages 260-277

  Ting, Daniel Shu Wei ^a,b   Cheung, Gemmy Chui Ming ^a,b,c   Wong, Tien Yin ^a,b,c  

^a Singapore Health Services   (Singapore)

^b SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; CANDESARTAN; ENALAPRIL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FENOFIBRATE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LISINOPRIL; LOSARTAN; PLACEBO; PROSTAGLANDIN E2; STROMAL CELL DERIVED FACTOR 1ALPHA; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

AGE DISTRIBUTION; AWARENESS; BLOOD PRESSURE REGULATION; BODY MASS; CATARACT EXTRACTION; CHROMOSOME 1P; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; EARLY DIAGNOSIS; EYE CARE; EYE EXAMINATION; EYE PHOTOGRAPHY; GENETIC RISK; GENOME-WIDE ASSOCIATION STUDY; GLYCEMIC CONTROL; HISPANIC; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; MASS SCREENING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OPHTHALMOSCOPY; OXIDATIVE STRESS; PRACTICE GUIDELINE; PREGNANCY; PREVALENCE; PROLIFERATIVE DIABETIC RETINOPATHY; PUBERTY; RETINAL PHOTOGRAPHY; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; SLIT LAMP; SYSTOLIC BLOOD PRESSURE; TELEMEDICINE; VISUAL ACUITY; VISUAL IMPAIRMENT; WAIST HIP RATIO;

EID: 84974782886     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/ceo.12696     Document Type: Review

References (194)

1. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998; 105: 998–1003.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes care 2004; 27: 1047–53.
3. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic epidemiology 2007; 14: 179–83.
4. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010; 376 (9735): 124–36.
5. International Diabetes Federation. Diabetes atlas, 6th ed, Brussels, Belgium. 2015.
6. Ferris FL 3rd. How effective are treatments for diabetic retinopathy? Jama 1993; 269: 1290–1.
7. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs – an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98: 786–806.
8. James M, Turner DA, Broadbent DM, Vora J, Harding SP. Cost effectiveness analysis of screening for sight threatening diabetic eye disease. BMJ 2000; 320: 1627–31.
9. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bulletin of the World Health Organization 2004; 82: 844–51.
10. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes care 2012; 35: 556–64.
11. Sivaprasad S, Gupta B, Crosby-Nwaobi R, Evans J. Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective. Survey of ophthalmology 2012; 57: 347–70.
12. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia 1994; 37: 278–85.
13. Roy MS, Klein R, O'Colmain BJ, Klein BE, Moss SE, Kempen JH. The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States. Archives of ophthalmology 2004; 122: 546–51.
14. Ramachandran A, Snehalatha C, Sasikala R, Satyavani K, Vijay V. Vascular complications in young Asian Indian patients with type 1 diabetes mellitus. Diabetes research and clinical practice 2000; 48: 51–6.
15. Ko GT, Chan JC, Lau M, Cockram CS. Diabetic microangiopathic complications in young Chinese diabetic patients: a clinic-based cross-sectional study. Journal of diabetes and its complications 1999; 13: 300–6.
16. Bonney M, Hing SJ, Fung AT, et al. Development and progression of diabetic retinopathy: adolescents at risk. Diabetic medicine: a journal of the British Diabetic Association 1995; 12: 967–73.
17. Fairchild JM, Hing SJ, Donaghue KC, et al. Prevalence and risk factors for retinopathy in adolescents with type 1 diabetes. Med J Aust 1994; 160: 757–62.
18. Scott A, Whitcombe S, Bouchier D, Dunn P. Diabetes in children and young adults in Waikato Province, New Zealand: outcomes of care. N Z Med J 2004; 117: U1219.
19. Maguire A, Chan A, Cusumano J, et al. The case for biennial retinopathy screening in children and adolescents. Diabetes care 2005; 28: 509–13.
20. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995; 102: 7–16.
21. Younis N, Broadbent DM, Vora JP, Harding SP. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. The Lancet 2003; 361: 195–200.
22. Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44: 156–63.
23. Giuffre G, Lodato G, Dardanoni G. Prevalence and risk factors of diabetic retinopathy in adult and elderly subjects: The Casteldaccia Eye Study. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle. Ophthalmologie 2004; 242: 535–40.
24. Hove MN, Kristensen JK, Lauritzen T, Bek T. The prevalence of retinopathy in an unselected population of type 2 diabetes patients from Arhus County, Denmark. Acta ophthalmologica Scandinavica 2004; 82: 443–8.
25. Knudsen LL, Lervang HH, Lundbye-Christensen S, Gorst-Rasmussen A. The North Jutland County Diabetic Retinopathy Study: population characteristics. Br J Ophthalmol 2006; 90: 1404–9.
26. Hamman RF, Mayer EJ, Moo-Young GA, Hildebrandt W, Marshall JA, Baxter J. Prevalence and risk factors of diabetic retinopathy in non-Hispanic whites and Hispanics with NIDDM. San Luis Valley Diabetes Study. Diabetes 1989; 38: 1231–7.
27. Varma R, Ying-Lai M, Klein R, Azen SP. Los Angeles Latino Eye Study G. Prevalence and risk indicators of visual impairment and blindness in Latinos: the Los Angeles Latino Eye Study. Ophthalmology 2004; 111: 1132–40.
28. Wong TY, Klein R, Islam FM, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. American journal of ophthalmology 2006; 141: 446–55.
29. Emanuele N, Sacks J, Klein R, et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes care 2005; 28: 1954–8.
30. Varma R, Paz SH, Azen SP, et al. The Los Angeles Latino Eye Study: design, methods, and baseline data. Ophthalmology 2004; 111: 1121–31.
31. Tapp RJ, Shaw JE, Harper CA, et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes care 2003; 26: 1731–7.
32. Mitchell P, Smith W, Wang JJ, Attebo K. Prevalence of diabetic retinopathy in an older community. The Blue Mountains Eye Study. Ophthalmology 1998; 105: 406–11.
33. McKay R, McCarty CA, Taylor HR. Diabetic retinopathy in Victoria, Australia: the Visual Impairment Project. British journal of ophthalmology 2000; 84: 865–70.
34. Mitchell P, Moffitt PS, Beaumont P. Prevalence of vision-threatening diabetic retinopathy in Newcastle, Australia. Tohoku J Exp Med 1983; 141: 379–83.
35. Mitchell P. Development and progression of diabetic eye disease in Newcastle (1977–1984): rates and risk factors. Australian and New Zealand journal of ophthalmology 1985; 13: 39–44.
36. He S, Guo Y, Li Z. Epidemiologic study of diabetic retinopathy in Capital Steel Company]. [Zhonghua yan ke za zhi. Chinese journal of ophthalmology 1997; 33: 381–3.
37. Raman R, Rani PK, Reddi Rachepalle S, et al. Prevalence of diabetic retinopathy in India: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study report 2. Ophthalmology 2009; 116: 311–8.
38. Wang FH, Liang YB, Zhang F, et al. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmology 2009; 116: 461–7.
39. Xie XW, Xu L, Wang YX, Jonas JB. Prevalence and associated factors of diabetic retinopathy. The Beijing Eye Study 2006. Graefe's archive for clinical and experimental ophthalmology. Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2008; 246: 1519–26.
40. Raman R, Ganesan S, Pal SS, Kulothungan V, Sharma T. Prevalence and risk factors for diabetic retinopathy in rural India. Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study III (SN-DREAMS III), report no 2. BMJ open diabetes research & care 2014; 2: e000005.
41. Chiang PP, Lamoureux EL, Cheung CY, et al. Racial differences in the prevalence of diabetes but not diabetic retinopathy in a multi-ethnic Asian population. Investigative ophthalmology & visual science 2011; 52: 7586–92.
42. Zheng Y, Lamoureux EL, Lavanya R, et al. Prevalence and risk factors of diabetic retinopathy in migrant Indians in an urbanized society in Asia: the Singapore Indian eye study. Ophthalmology 2012; 119: 2119–24.
43. Burger W, Hovener G, Dusterhus R, Hartmann R, Weber B. Prevalence and development of retinopathy in children and adolescents with type 1 (insulin-dependent) diabetes mellitus. A longitudinal study. Diabetologia 1986; 29: 17–22.
44. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008; 115: 1859–68.
45. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009; 116: 497–503.
46. Jones CD, Greenwood RH, Misra A, Bachmann MO. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes care 2012; 35: 592–6.
47. Leske MC, Wu SY, Hennis A, et al. Incidence of diabetic retinopathy in the Barbados Eye Studies. Ophthalmology 2003; 110: 941–7.
48. Cikamatana L, Mitchell P, Rochtchina E, Foran S, Wang JJ. Five-year incidence and progression of diabetic retinopathy in a defined older population: the Blue Mountains Eye Study. Eye (Lond) 2007; 21: 465–71.
49. Song H, Liu L, Sum R, Fung M, Yap MK. Incidence of diabetic retinopathy in a Hong Kong Chinese population. Clinical & experimental optometry: journal of the Australian Optometrical Association 2011; 94: 563–7.
50. Wong TY, Mwamburi M, Klein R, et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes care 2009; 32: 2307–13.
51. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. The New England journal of medicine 1993; 329: 977–86.
52. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology 1995; 102: 647–61.
53. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. The New England journal of medicine 2000; 342: 381–9.
54. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–53.
55. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. Jama 2007; 298: 902–16.
56. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. The New England journal of medicine 2008; 359: 1577–89.
57. Drzewoski J, Kasznicki J, Trojanowski Z. The role of “metabolic memory” in the natural history of diabetes mellitus. Pol Arch Med Wewn 2009; 119 (7–8): 493–500.
58. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Archives of ophthalmology 1998; 116: 874–86.
59. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993; 341: 1306–9.
60. Group AS, Group AES, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. The New England journal of medicine 2010; 363: 233–44.
61. Zoungas S, Chalmers J, Ninomiya T, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 2012; 55: 636–43.
62. Klein R, Moss SE, Klein BE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. Ophthalmology 1989; 96: 1501–10.
63. Wong TY, Mitchell P. The eye in hypertension. Lancet 2007; 369: 425–35.
64. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Archives of internal medicine 1989; 149: 2427–32.
65. Mitchell P, Wong TY. DIRECT new treatments for diabetic retinopathy. Lancet 2008; 372: 1361–3.
66. Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008; 372: 1394–402.
67. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. The New England journal of medicine 2009; 361: 40–51.
68. Sjolie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008; 372: 1385–93.
69. Mauer M, Zinman B, Gardiner R, et al. ACE-I and ARBs in early diabetic nephropathy. Journal of the renin–angiotensin–aldosterone system: JRAAS 2002; 3: 262–9.
70. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351(9095): 28–31.
71. Schrier RW, Savage S. Appropriate blood pressure control in type II diabetes (ABCD Trial): implications for complications. Am J Kidney Dis 1992; 20: 653–7.
72. Wong TY, Cheung N, Tay WT, et al. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology 2008; 115: 1869–75.
73. Raman R, Rani PK, Kulothungan V, Rachepalle SR, Kumaramanickavel G, Sharma T. Influence of serum lipids on clinically significant versus nonclinically significant macular edema: SN-DREAMS Report number 13. Ophthalmology 2010; 117: 766–72.
74. Rema M, Srivastava BK, Anitha B, Deepa R, Mohan V. Association of serum lipids with diabetic retinopathy in urban South Indians – the Chennai Urban Rural Epidemiology Study (CURES) Eye Study – 2. Diabetic medicine: a journal of the British Diabetic Association 2006; 23: 1029–36.
75. Lyons TJ, Jenkins AJ, Zheng D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Investigative ophthalmology & visual science 2004; 45: 910–8.
76. Keech AC MP, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet 2007; 370: 1687–97.
77. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Archives of ophthalmology 1984; 102: 520–6.
78. Klein R, Klein BE, Moss SE. Is obesity related to microvascular and macrovascular complications in diabetes? The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Archives of internal medicine 1997; 157: 650–6.
79. Lim LS, Tai ES, Mitchell P, et al. C-reactive protein, body mass index, and diabetic retinopathy. Investigative ophthalmology & visual science 2010; 51: 4458–63.
80. Henricsson M, Nystrom L, Blohme G, et al. The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes care 2003; 26: 349–54.
81. Chaturvedi N, Sjoelie AK, Porta M, et al. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes care 2001; 24: 284–9.
82. van Hecke MV, Dekker JM, Stehouwer CD, et al. Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study. Diabetes care 2005; 28: 1383–9.
83. Soedamah-Muthu SS, Chaturvedi N, Toeller M, et al. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes care 2004; 27: 530–7.
84. Vestgaard M, Ringholm L, Laugesen CS, Rasmussen KL, Damm P, Mathiesen ER. Pregnancy-induced sight-threatening diabetic retinopathy in women with Type 1 diabetes. Diabetic medicine: a journal of the British Diabetic Association 2010; 27: 431–5.
85. Rasmussen KL, Laugesen CS, Ringholm L, Vestgaard M, Damm P, Mathiesen ER. Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes. Diabetologia 2010; 53: 1076–83.
86. Klein BE, Moss SE, Klein R. Is menarche associated with diabetic retinopathy? Diabetes care 1990; 13: 1034–8.
87. Donaghue KC, Fairchild JM, Craig ME, et al. Do all prepubertal years of diabetes duration contribute equally to diabetes complications? Diabetes care 2003; 26: 1224–9.
88. Olsen BS, Sjolie AK, Hougaard P, et al. The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes. Journal of diabetes and its complications 2004; 18: 160–4.
89. Diabetes C. Complications Trial Research G. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes care 2000; 23: 1084–91.
90. Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes care 1990; 13: 34–40.
91. Stalnikiewicz L, Floriot M, Guerci B, Angioi K. Progression of diabetic retinopathy during pregnancy: a retrospective analysis of a series of 77 consecutive patients. Journal francais d'ophtalmologie 2010; 33: 481–6.
92. Sunness JS. The pregnant woman's eye. Survey of ophthalmology 1988; 32: 219–38.
93. Chew EY, Benson WE, Remaley NA, et al. Results after lens extraction in patients with diabetic retinopathy: early treatment diabetic retinopathy study report number 25. Archives of ophthalmology 1999; 117: 1600–6.
94. Shah AS, Chen SH. Cataract surgery and diabetes. Current opinion in ophthalmology 2010; 21: 4–9.
95. Henricsson M, Heijl A, Janzon L. Diabetic retinopathy before and after cataract surgery. Br J Ophthalmol 1996; 80: 789–93.
96. Suto C, Kitano S, Hori S. Optimal timing of cataract surgery and panretinal photocoagulation for diabetic retinopathy. Diabetes care 2011; 34: e123.
97. Lim LS, Wong TY. Lipids and diabetic retinopathy. Expert opinion on biological therapy 2012; 12: 93–105.
98. Spijkerman AM, Gall MA, Tarnow L, et al. Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in Type 2 diabetes. Diabetic medicine: a journal of the British Diabetic Association 2007; 24: 969–76.
99. van Hecke MV, Dekker JM, Nijpels G, et al. Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia 2005; 48: 1300–6.
100. Meleth AD, Agron E, Chan CC, et al. Serum inflammatory markers in diabetic retinopathy. Investigative ophthalmology & visual science 2005; 46: 4295–301.
101. Nowak M, Wielkoszynski T, Marek B, et al. Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy. Clinical and experimental medicine 2010; 10: 185–92.
102. Nowak M, Wielkoszynski T, Marek B, et al. Blood serum levels of vascular cell adhesion molecule (sVCAM-1), intercellular adhesion molecule (sICAM-1) and endothelial leucocyte adhesion molecule-1 (ELAM-1) in diabetic retinopathy. Clinical and experimental medicine 2008; 8: 159–64.
103. Gustavsson C, Agardh E, Bengtsson B, Agardh CD. TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. Journal of diabetes and its complications 2008; 22: 309–16.
104. Muni RH, Kohly RP, Lee EQ, Manson JE, Semba RD, Schaumberg DA. Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial. JAMA ophthalmology 2013; 131: 514–21.
105. Kuo JZ, Wong TY, Rotter JI. Challenges in elucidating the genetics of diabetic retinopathy. JAMA ophthalmology 2014; 132: 96–107.
106. Leslie RD, Pyke DA. Diabetic retinopathy in identical twins. Diabetes 1982; 31: 19–21.
107. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997; 46(11): 1829–39.
108. Hietala K, Forsblom C, Summanen P, Groop PH, FinnDiane SG. Heritability of proliferative diabetic retinopathy. Diabetes 2008; 57: 2176–80.
109. Looker HC, Nelson RG, Chew E, et al. Genome-wide linkage analyses to identify Loci for diabetic retinopathy. Diabetes 2007; 56: 1160–6.
110. Zhang X, Gao Y, Zhou Z, Wang J, Zhou Q, Li Q. Familial clustering of diabetic retinopathy in Chongqing, China, type 2 diabetic patients. European journal of ophthalmology 2010; 20: 911–8.
111. Rema M, Saravanan G, Deepa R, Mohan V. Familial clustering of diabetic retinopathy in South Indian Type 2 diabetic patients. Diabetic medicine: a journal of the British Diabetic Association 2002; 19: 910–6.
112. Hallman DM, Huber JC Jr, Gonzalez VH, Klein BE, Klein R, Hanis CL. Familial aggregation of severity of diabetic retinopathy in Mexican Americans from Starr County, Texas. Diabetes care 2005; 28: 1163–8.
113. Arar NH, Freedman BI, Adler SG, et al. Heritability of the severity of diabetic retinopathy: the FIND-Eye study. Investigative ophthalmology & visual science 2008; 49: 3839–45.
114. Liew G, Klein R, Wong TY. The role of genetics in susceptibility to diabetic retinopathy. International ophthalmology clinics 2009; 49: 35–52.
115. Ng DP. Human genetics of diabetic retinopathy: current perspectives. Journal of ophthalmology 2010; 2010.
116. Abhary S, Hewitt AW, Burdon KP, Craig JE. A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes 2009; 58: 2137–47.
117. Zhao T, Zhao J. Association between the −634C/G polymorphisms of the vascular endothelial growth factor and retinopathy in type 2 diabetes: a meta-analysis. Diabetes research and clinical practice 2010; 90: 45–53.
118. Hallman DM, Boerwinkle E, Gonzalez VH, Klein BE, Klein R, Hanis CL. A genome-wide linkage scan for diabetic retinopathy susceptibility genes in Mexican Americans with type 2 diabetes from Starr County. Texas. Diabetes 2007; 56: 1167–73.
119. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. Diabetes 1998; 47: 821–30.
120. Fu YP, Hallman DM, Gonzalez VH, et al. Identification of diabetic retinopathy genes through a genome-wide association study among Mexican–Americans from Starr County, Texas. Journal of ophthalmology 2010; 2010.
121. Huang YC, Lin JM, Lin HJ, et al. Genome-wide association study of diabetic retinopathy in a Taiwanese population. Ophthalmology 2011; 118: 642–8.
122. Grassi MA, Tikhomirov A, Ramalingam S, Below JE, Cox NJ, Nicolae DL. Genome-wide meta-analysis for severe diabetic retinopathy. Hum Mol Genet 2011; 20: 2472–81.
123. Kumaramanickavel G, Sripriya S, Ramprasad VL, Upadyay NK, Paul PG, Sharma T. Z-2 aldose reductase allele and diabetic retinopathy in India. Ophthalmic genetics 2003; 24: 41–8.
124. Olmos P, Bastias MJ, Vollrath V, et al. C(−106)T polymorphism of the aldose reductase gene and the progression rate of diabetic retinopathy. Diabetes research and clinical practice 2006; 74: 175–82.
125. Kumaramanickavel G, Ramprasad VL, Sripriya S, Upadyay NK, Paul PG, Sharma T. Association of Gly82Ser polymorphism in the RAGE gene with diabetic retinopathy in type II diabetic Asian Indian patients. Journal of diabetes and its complications 2002; 16: 391–4.
126. Beranek M, Kankova K, Benes P, et al. Polymorphism R25P in the gene encoding transforming growth factor-beta (TGF-beta1) is a newly identified risk factor for proliferative diabetic retinopathy. American journal of medical genetics 2002; 109: 278–83.
127. Errera FI, Canani LH, Silva ME, et al. Functional vascular endothelial growth factor −634G > C SNP is associated with proliferative diabetic retinopathy: a case–control study in a Brazilian population of European ancestry. Diabetes care 2007; 30: 275–9.
128. Suganthalakshmi B, Anand R, Kim R, et al. Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Molecular vision 2006; 12: 336–41.
129. Rietveld I, Ikram MK, Vingerling JR, et al. An igf-I gene polymorphism modifies the risk of diabetic retinopathy. Diabetes 2006; 55: 2387–91.
130. Sheu WH, Kuo JZ, Lee IT, et al. Genome-wide association study in a Chinese population with diabetic retinopathy. Hum Mol Genet 2013; 22: 3165–73.
131. Hammond C, Shackleton J, Flanagan DW, Herrtage J, Wade J. Comparison between an ophthalmic optician and ophthalmologist in screening for diabetic retinopathy. Eye 1996: 107–12.
132. Buxton M, Sculpher MJ, Ferguson BA et al. Screening for treatable diabetic retinopathy: a comparison of different methods. DiabetMed 1991; 8: 371–7.
133. Lienert R. Inter-observer comparisons of ophthalmoscopic assessment of diabetic retinopathy. AustNZJOphthalmol 1989; 17: 363–8.
134. Hutchinson A, McIntosh A, Peters J, et al. Effectiveness of screening and monitoring tests for diabetic retinopathy – a systematic review. Diabetic medicine: a journal of the British Diabetic Association 2000; 17: 495–506.
135. Scanlon PH, Malhotra R, Greenwood RH, et al. Comparison of two reference standards in validating two field mydriatic digital photography as a method of screening for diabetic retinopathy. Br J Ophthalmol 2003; 87: 1258–63.
136. Murray R, Metcalf SM, Lewis PM, Mein JK, McAllister IL. Sustainingremote-area programs: retinal camera use by Aboriginal health workers and nurses in a Kimberley partnership. MedJ Aust 2005; 182: 520–3.
137. Ting DS, Tay-Kearney ML, Constable I, Lim L, Preen DB, Kanagasingam Y. Retinal video recording a new way to image and diagnose diabetic retinopathy. Ophthalmology 2011; 118: 1588–93.
138. International Council of Ophthalmology. Diabetic Eye Care. ICO Guidelines for Diabetic Eye Care. 2014. http://www.icoph.org/taskforce-documents/diabetic-retinopathy-guidelines.html.
139. Goldberg M, Fine S. Symposium on the Treatment of Diabetic Retinopathy, Airlie House, Warrenton, Virginia.: Department of Health, Education and Welfare.; 1968.
140. Davis MD, Hubbard LD, Trautman J, Klein R. Conference on insulin pump therapy in diabetes. Multicenter study effect on microvascular disease. Studies of retinopathy. Methodology for assessment and classification with fundus photographs. Diabetes 1985; 34 Suppl 3: 42–9.
141. Kohner EPM. Screening for diabetic retinopathy: A field guide-book, 1992.
142. Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110: 1677–82.
143. National Institute for Clinical Excellence. Diabetic retinopathy – early management and screening. London, UK 2001.
144. Scanlon PH. The English national screening programme for sight-threatening diabetic retinopathy. J Med Screen 2008; 15: 1–4.
145. Liew G, Mitchell P, Wang JJ, Wong TY. Fundoscopy: to dilate or not to dilate? BMJ 2006; 332: 3.
146. Fransen S, Leonard-Martin TC, Feuer WJ, Hildebrand PL. Clinical evaluation of patients with diabetic retinopathy: accuracy of the Inoveon diabetic retinopathy-3DT system. Ophthalmology 2002; 109: 595–601.
147. Lin D, Blumenkranz M, Brothers R, Grosvenor D. The sensitivity and specificity of single-field nonmydriatic monochromatic digital fundus photography with remote image interpretation for diabetic retinopathy screening: a comparison with ophthalmoscopy and standardized mydriatic color photography. American journal of ophthalmology 2002; 134: 204–13.
148. Khan T, Bertram MY, Jina R, Mash B, Levitt N, Hofman K. Preventing diabetes blindness: cost effectiveness of a screening programme using digital non-mydriatic fundus photography for diabetic retinopathy in a primary health care setting in South Africa. Diabetes research and clinical practice 2013; 101: 170–6.
149. Silva PS, Cavallerano JD, Tolls D, et al. Potential efficiency benefits of nonmydriatic ultrawide field retinal imaging in an ocular telehealth diabetic retinopathy program. Diabetes care 2014; 37: 50–5.
150. Wessel MM, Aaker GD, Parlitsis G, Cho M, D'Amico DJ, Kiss S. Ultra-wide-field angiography improves the detection and classification of diabetic retinopathy. Retina 2012; 32: 785–91.
151. Olson JA, Strachan FM, Hipwell JH, et al. A comparative evaluation of digital imaging, retinal photography and optometrist examination in screening for diabetic retinopathy. Diabetic medicine: a journal of the British Diabetic Association 2003; 20: 528–34.
152. Kumar S, Tay-Kearney ML, Constable IJ, Yogesan K. Internet based ophthalmology service: impact assessment. The British journal of ophthalmology 2005; 89: 1382–3.
153. Kumar S, Tay-Kearney ML, Chaves F, Constable IJ, Yogesan K. Remote ophthalmology services: cost comparison of telemedicine and alternative service delivery options. J Telemed Telecare 2006; 12: 10–22.
154. Sharma M, Chakrabarty AS, Pavan R, Sharma R, Pratibha G. An integrated, mobile service for diabetic retinopathy in rural India. Community eye health/ International Centre for Eye Health 2011; 24: 17–8.
155. Bursell SE, Cavallerano JD, Cavallerano AA, et al. Stereo nonmydriatic digital-video color retinal imaging compared with Early Treatment Diabetic Retinopathy Study seven standard field 35-mm stereo color photos for determining level of diabetic retinopathy. Ophthalmology 2001; 108: 572–85.
156. Conlin PR, Fisch BM, Orcutt JC, Hetrick BJ, Darkins AW. Framework for a national teleretinal imaging program to screen for diabetic retinopathy in Veterans Health Administration patients. J Rehabil Res Dev 2006; 43: 741–8.
157. Cavallerano AA, Cavallerano JD, Katalinic P, et al. A telemedicine program for diabetic retinopathy in a Veterans Affairs Medical Center – the Joslin Vision Network Eye Health Care Model. American journal of ophthalmology 2005; 139: 597–604.
158. National Health Service (NHS). National Screening Programme for Diabetic Retinopathy.
159. American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2012. Diabetes care: 1–11.
160. Raikou M, McGuire A. The economics of screening and treatment in type 2 diabetes mellitus. PharmacoEconomics 2003; 21: 543–64.
161. Javitt JC, Aiello LP, Chiang Y, Ferris FL 3rd, Canner JK, Greenfield S. Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diabetes care 1994; 17: 909–17.
162. Javitt JC, Aiello LP, Bassi LJ, Chiang YP, Canner JK. Detecting and treating retinopathy in patients with type I diabetes mellitus. Savings associated with improved implementation of current guidelines. American Academy of Ophthalmology. Ophthalmology 1991; 98: 1565–73 discussion 74.
163. Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Annals of internal medicine 1996; 124: 164–9.
164. Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Archives of ophthalmology 2006; 124: 1754–60.
165. Heintz E, Wirehn AB, Peebo BB, Rosenqvist U, Levin LA. Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden. Diabetologia 2010; 53: 2147–54.
166. Australia D. The Economic Impact of Diabetic Macular Oedema in Australia, 2015.
167. Wang S, Tikellis G, Wong N, Wong TY, Wang JJ. Lack of knowledge of glycosylated hemoglobin in patients with diabetic retinopathy. Diabetes research and clinical practice 2008; 81: e15–7.
168. Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes care 2002; 25: 1159–71.
169. Morrison F, Shubina M, Turchin A. Lifestyle counseling in routine care and long-term glucose, blood pressure, and cholesterol control in patients with diabetes. Diabetes care 2012; 35: 334–41.
170. Aiello LP, Ayala AR, Antoszyk AN, et al. Assessing the effect of personalized diabetes risk assessments during ophthalmologic visits on glycemic control: a randomized clinical trial. JAMA ophthalmology 2015; 133: 888–96.
171. Fenwick E, Rees G, Pesudovs K, et al. Social and emotional impact of diabetic retinopathy: a review. Clinical & experimental ophthalmology 2012; 40: 27–38.
172. Fenwick EK, Pesudovs K, Rees G, et al. The impact of diabetic retinopathy: understanding the patient's perspective. Br J Ophthalmol 2011; 95: 774–82.
173. Safren SA, Gonzalez JS, Wexler DJ, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in patients with uncontrolled type 2 diabetes. Diabetes care 2014; 37: 625–33.
174. Cox DJ, Kiernan BD, Schroeder DB, Cowley M. Psychosocial sequelae of visual loss in diabetes. Diabetes Educ 1998; 24: 481–4.
175. Trento M, Tomelini M, Lattanzio R, et al. Perception of, and anxiety levels induced by, laser treatment in patients with sight-threatening diabetic retinopathy. A multicentre study. Diabetic medicine: a journal of the British Diabetic Association 2006; 23: 1106–9.
176. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Archives of internal medicine 2006; 166: 1836–41.
177. Serlachius AS, Scratch SE, Northam EA, Frydenberg E, Lee KJ, Cameron FJ. A randomized controlled trial of cognitive behaviour therapy to improve glycaemic control and psychosocial wellbeing in adolescents with type 1 diabetes. J Health Psychol 2014.
178. Dornhorst A, Merrin PK. Primary, secondary and tertiary prevention of non-insulin-dependent diabetes. Postgraduate medical journal 1994; 70: 529–35.
179. Balkau B, Mhamdi L, Oppert JM, et al. Physical activity and insulin sensitivity: the RISC study. Diabetes 2008; 57: 2613–8.
180. Bessesen DH. The role of carbohydrates in insulin resistance. J Nutr 2001; 131: 2782S–6S.
181. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology 1981; 88: 583–600.
182. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group. Archives of ophthalmology 1985; 103: 1644–52.
183. Harding S, Greenwood R, Aldington S, et al. Grading and disease management in national screening for diabetic retinopathy in England and Wales. Diabetic medicine: a journal of the British Diabetic Association 2003; 20: 965–71.
184. Scanlon PH, Aldington SJ, Leal J, et al. Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. Health Technol Assess 2015; 19: 1–116.
185. National Health Service, England, United Kingdom. Diabetic eye screening: commission and provide. 2015.
186. Jones S, Edwards RT. Diabetic retinopathy screening: a systematic review of the economic evidence. Diabetic medicine: a journal of the British Diabetic Association 2010; 27: 249–56.
187. Rachapelle S, Legood R, Alavi Y, et al. The cost-utility of telemedicine to screen for diabetic retinopathy in India. Ophthalmology 2013; 120: 566–73.
188. Lairson DR, Pugh JA, Kapadia AS, Lorimor RJ, Jacobson J, Velez R. Cost-effectiveness of alternative methods for diabetic retinopathy screening. Diabetes care 1992; 15: 1369–77.
189. Diabetic Retinopathy Clinical Research N, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. The New England journal of medicine 2015; 372: 1193–203.
190. Diabetic Retinopathy Clinical Research N, Elman MJ, Aiello LP, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064–77 e35.
191. Xu H. P. Z. Present condition of ophthalmology resource in China in 2000. Medicine and Society 2005; 18: 7–9.
192. Gibbins RL, Owens DR, Allen JC, Eastman L. Practical application of the European Field Guide in screening for diabetic retinopathy by using ophthalmoscopy and 35 mm retinal slides. Diabetologia 1998; 41: 59–64.
193. Ting DS, Tay-Kearney ML, Kanagasingam Y. Light and portable novel device for diabetic retinopathy screening. Clinical & experimental ophthalmology 2012; 40: e40–6.
194. Pugh JA, Jacobson JM, Van Heuven WA, et al. Screening for diabetic retinopathy. The wide-angle retinal camera. Diabetes care 1993; 16: 889–95.